Anupam Rama
Stock Analyst at JP Morgan
(3.07)
# 1,132
Out of 4,814 analysts
262
Total ratings
37.26%
Success rate
0.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Anupam Rama
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OLMA Olema Pharmaceuticals | Maintains: Overweight | $30 → $28 | $4.26 | +557.28% | 4 | Mar 28, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $104 → $117 | $35.64 | +228.28% | 3 | Mar 27, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $183 → $184 | $100.10 | +83.82% | 17 | Mar 26, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $44 → $50 | $34.24 | +46.03% | 9 | Mar 24, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $39 → $41 | $11.51 | +256.21% | 10 | Mar 20, 2025 | |
| ZLAB Zai Lab | Maintains: Overweight | $44 → $51 | $28.86 | +76.72% | 12 | Mar 13, 2025 | |
| SLDB Solid Biosciences | Maintains: Overweight | $12 → $11 | $2.56 | +330.53% | 7 | Mar 13, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Overweight | $39 → $34 | $6.76 | +402.96% | 4 | Mar 5, 2025 | |
| ANAB AnaptysBio | Maintains: Overweight | $36 → $42 | $20.58 | +104.08% | 11 | Mar 5, 2025 | |
| VERA Vera Therapeutics | Maintains: Overweight | $77 → $71 | $21.19 | +235.06% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $54 | $18.17 | +197.19% | 16 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $44 | $14.92 | +194.91% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $18 | $7.96 | +126.13% | 8 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $21 → $22 | $4.77 | +361.70% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $8.36 | +258.85% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $19 → $21 | $4.34 | +383.87% | 4 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $17 | $6.83 | +149.08% | 13 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.79 | - | 7 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $40 | $20.21 | +97.92% | 3 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $125 | $71.73 | +74.26% | 6 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $0.71 | - | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $64 → $68 | $37.89 | +79.47% | 5 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $69 → $66 | $16.93 | +289.84% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $12 → $10 | $7.44 | +34.50% | 7 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.25 | - | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $177 → $175 | $53.79 | +225.34% | 11 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $0.65 | - | 3 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $1.46 | +793.47% | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $9 | $0.39 | +2,201.20% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.84 | - | 6 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.39 | - | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 | $6.16 | +3,958.44% | 7 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.31 | - | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $58 | $39.48 | +46.91% | 1 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 → $12 | $8.62 | +39.21% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $29 → $37 | $5.47 | +577.04% | 6 | Oct 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $55 | $46.32 | +18.74% | 3 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $1.16 | +2,324.24% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $54 | $27.66 | +95.23% | 10 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $0.32 | +13,870.82% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $8.18 | +230.28% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $6.45 | +520.16% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $133 → $137 | $234.75 | -41.64% | 9 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $39 | $4.69 | +731.56% | 1 | Dec 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $48 | $4.33 | +1,009.83% | 5 | Jul 12, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $10.30 | - | 2 | May 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $18 | $0.86 | +2,002.31% | 2 | Mar 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $1.06 | +2,730.19% | 1 | Dec 4, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $47.45 | - | 2 | Nov 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.73 | - | 2 | Jul 21, 2017 |
Olema Pharmaceuticals
Mar 28, 2025
Maintains: Overweight
Price Target: $30 → $28
Current: $4.26
Upside: +557.28%
Ultragenyx Pharmaceutical
Mar 27, 2025
Maintains: Overweight
Price Target: $104 → $117
Current: $35.64
Upside: +228.28%
Neurocrine Biosciences
Mar 26, 2025
Maintains: Overweight
Price Target: $183 → $184
Current: $100.10
Upside: +83.82%
BridgeBio Pharma
Mar 24, 2025
Maintains: Overweight
Price Target: $44 → $50
Current: $34.24
Upside: +46.03%
Syndax Pharmaceuticals
Mar 20, 2025
Maintains: Overweight
Price Target: $39 → $41
Current: $11.51
Upside: +256.21%
Zai Lab
Mar 13, 2025
Maintains: Overweight
Price Target: $44 → $51
Current: $28.86
Upside: +76.72%
Solid Biosciences
Mar 13, 2025
Maintains: Overweight
Price Target: $12 → $11
Current: $2.56
Upside: +330.53%
Day One Biopharmaceuticals
Mar 5, 2025
Maintains: Overweight
Price Target: $39 → $34
Current: $6.76
Upside: +402.96%
AnaptysBio
Mar 5, 2025
Maintains: Overweight
Price Target: $36 → $42
Current: $20.58
Upside: +104.08%
Vera Therapeutics
Mar 4, 2025
Maintains: Overweight
Price Target: $77 → $71
Current: $21.19
Upside: +235.06%
Mar 4, 2025
Maintains: Overweight
Price Target: $50 → $54
Current: $18.17
Upside: +197.19%
Feb 26, 2025
Maintains: Overweight
Price Target: $42 → $44
Current: $14.92
Upside: +194.91%
Feb 26, 2025
Maintains: Overweight
Price Target: $16 → $18
Current: $7.96
Upside: +126.13%
Feb 26, 2025
Maintains: Overweight
Price Target: $21 → $22
Current: $4.77
Upside: +361.70%
Feb 25, 2025
Initiates: Overweight
Price Target: $30
Current: $8.36
Upside: +258.85%
Nov 14, 2024
Maintains: Overweight
Price Target: $19 → $21
Current: $4.34
Upside: +383.87%
Nov 12, 2024
Maintains: Overweight
Price Target: $16 → $17
Current: $6.83
Upside: +149.08%
Nov 11, 2024
Downgrades: Underweight
Price Target: n/a
Current: $0.79
Upside: -
Nov 5, 2024
Maintains: Overweight
Price Target: $39 → $40
Current: $20.21
Upside: +97.92%
Oct 4, 2024
Maintains: Overweight
Price Target: $100 → $125
Current: $71.73
Upside: +74.26%
Sep 30, 2024
Initiates: Neutral
Price Target: n/a
Current: $0.71
Upside: -
Sep 4, 2024
Maintains: Overweight
Price Target: $64 → $68
Current: $37.89
Upside: +79.47%
Aug 8, 2024
Maintains: Overweight
Price Target: $69 → $66
Current: $16.93
Upside: +289.84%
Aug 6, 2024
Maintains: Neutral
Price Target: $12 → $10
Current: $7.44
Upside: +34.50%
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.25
Upside: -
May 3, 2024
Maintains: Overweight
Price Target: $177 → $175
Current: $53.79
Upside: +225.34%
Apr 22, 2024
Upgrades: Neutral
Price Target: n/a
Current: $0.65
Upside: -
Apr 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $1.46
Upside: +793.47%
Aug 16, 2023
Maintains: Neutral
Price Target: $8 → $9
Current: $0.39
Upside: +2,201.20%
Jul 25, 2023
Downgrades: Underweight
Price Target: n/a
Current: $2.84
Upside: -
Nov 10, 2022
Downgrades: Underweight
Price Target: n/a
Current: $0.39
Upside: -
Jul 13, 2022
Downgrades: Neutral
Price Target: $250
Current: $6.16
Upside: +3,958.44%
Mar 8, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.31
Upside: -
Dec 10, 2021
Initiates: Overweight
Price Target: $58
Current: $39.48
Upside: +46.91%
Nov 5, 2021
Upgrades: Neutral
Price Target: $7 → $12
Current: $8.62
Upside: +39.21%
Oct 25, 2021
Upgrades: Neutral
Price Target: $29 → $37
Current: $5.47
Upside: +577.04%
Oct 12, 2021
Upgrades: Overweight
Price Target: $55
Current: $46.32
Upside: +18.74%
Aug 10, 2021
Initiates: Overweight
Price Target: $28
Current: $1.16
Upside: +2,324.24%
Mar 1, 2021
Downgrades: Neutral
Price Target: $54
Current: $27.66
Upside: +95.23%
Jan 11, 2021
Initiates: Overweight
Price Target: $45
Current: $0.32
Upside: +13,870.82%
Oct 12, 2020
Initiates: Overweight
Price Target: $27
Current: $8.18
Upside: +230.28%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $6.45
Upside: +520.16%
May 7, 2020
Downgrades: Neutral
Price Target: $133 → $137
Current: $234.75
Upside: -41.64%
Dec 24, 2019
Initiates: Overweight
Price Target: $39
Current: $4.69
Upside: +731.56%
Jul 12, 2019
Downgrades: Neutral
Price Target: $29 → $48
Current: $4.33
Upside: +1,009.83%
May 10, 2018
Upgrades: Overweight
Price Target: n/a
Current: $10.30
Upside: -
Mar 6, 2018
Maintains: Overweight
Price Target: $15 → $18
Current: $0.86
Upside: +2,002.31%
Dec 4, 2017
Initiates: Overweight
Price Target: $30
Current: $1.06
Upside: +2,730.19%
Nov 16, 2017
Upgrades: Neutral
Price Target: n/a
Current: $47.45
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $0.73
Upside: -